Case series data indicate that CD20 B cell depletion can be effective in MOGAD; however, refractory cases occur more frequently than in AQP4 NMO and relapses can be seen in up to 50% of patients (n = 121) despite efficient B cell depletion [124, 145, 146]. This evidence concerns the gene AQP4 and neuromyelitis optica.